Daniel Barenboim, Parkinson's disease
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback